Kallistatin inhibits tumour progression and platinum resistance in high-grade serous ovarian cancer
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1757-2215
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Kallistatin inhibits tumour progression and platinum resistance in high-grade serous ovarian cancer ; volume:12 ; number:1 ; day:29 ; month:12 ; year:2019 ; pages:1-10 ; date:12.2019
Journal of ovarian research ; 12, Heft 1 (29.12.2019), 1-10, 12.2019
- Urheber
-
Wu, Huan
Li, Rongrong
Zhang, Zhiwei
Jiang, Huiyang
Ma, Hanlin
Yuan, Cunzhong
Sun, Chenggong
Li, Yingwei
Kong, Beihua
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s13048-019-0601-6
- URN
-
urn:nbn:de:101:1-2020053022473225912918
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:47 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Wu, Huan
- Li, Rongrong
- Zhang, Zhiwei
- Jiang, Huiyang
- Ma, Hanlin
- Yuan, Cunzhong
- Sun, Chenggong
- Li, Yingwei
- Kong, Beihua
- SpringerLink (Online service)
Ähnliche Objekte (12)
Correction to: Kallistatin inhibits tumour progression and platinum resistance in high-grade serous ovarian cancer
PARP inhibitors in platinum-sensitive high-grade serous ovarian cancer
Aurora Kinase A expression predicts platinum-resistance and adverse outcome in high-grade serous ovarian carcinoma patients
Histopathologic image–based deep learning classifier for predicting platinum-based treatment responses in high-grade serous ovarian cancer
Morphologic and molecular correlates of EZH2 as a predictor of platinum resistance in high-grade ovarian serous carcinoma
Methylome analysis of extreme chemoresponsive patients identifies novel markers of platinum sensitivity in high-grade serous ovarian cancer
High-grade serous ovarian cancer: the clone wars
High-grade serous carcinoma with discordant p53 signature: report of a case with new insight regarding high-grade serous carcinogenesis
Homologous recombination deficiency status predicts response to platinum-based chemotherapy in Chinese patients with high-grade serous ovarian carcinoma
Benign serous ovarian tumour: a redefining moment?
Network vulnerability-based and knowledge-guided identification of microRNA biomarkers indicating platinum resistance in high-grade serous ovarian cancer
The CHK1 inhibitor prexasertib in BRCA wild-type platinum-resistant recurrent high-grade serous ovarian carcinoma: a phase 2 trial
Correction to: Kallistatin inhibits tumour progression and platinum resistance in high-grade serous ovarian cancer
PARP inhibitors in platinum-sensitive high-grade serous ovarian cancer
Aurora Kinase A expression predicts platinum-resistance and adverse outcome in high-grade serous ovarian carcinoma patients
Histopathologic image–based deep learning classifier for predicting platinum-based treatment responses in high-grade serous ovarian cancer
Morphologic and molecular correlates of EZH2 as a predictor of platinum resistance in high-grade ovarian serous carcinoma
Methylome analysis of extreme chemoresponsive patients identifies novel markers of platinum sensitivity in high-grade serous ovarian cancer
High-grade serous ovarian cancer: the clone wars
High-grade serous carcinoma with discordant p53 signature: report of a case with new insight regarding high-grade serous carcinogenesis
Homologous recombination deficiency status predicts response to platinum-based chemotherapy in Chinese patients with high-grade serous ovarian carcinoma
Benign serous ovarian tumour: a redefining moment?
Network vulnerability-based and knowledge-guided identification of microRNA biomarkers indicating platinum resistance in high-grade serous ovarian cancer
The CHK1 inhibitor prexasertib in BRCA wild-type platinum-resistant recurrent high-grade serous ovarian carcinoma: a phase 2 trial
Correction to: Kallistatin inhibits tumour progression and platinum resistance in high-grade serous ovarian cancer
PARP inhibitors in platinum-sensitive high-grade serous ovarian cancer
Aurora Kinase A expression predicts platinum-resistance and adverse outcome in high-grade serous ovarian carcinoma patients
Histopathologic image–based deep learning classifier for predicting platinum-based treatment responses in high-grade serous ovarian cancer
Morphologic and molecular correlates of EZH2 as a predictor of platinum resistance in high-grade ovarian serous carcinoma
Methylome analysis of extreme chemoresponsive patients identifies novel markers of platinum sensitivity in high-grade serous ovarian cancer
High-grade serous ovarian cancer: the clone wars
High-grade serous carcinoma with discordant p53 signature: report of a case with new insight regarding high-grade serous carcinogenesis
Homologous recombination deficiency status predicts response to platinum-based chemotherapy in Chinese patients with high-grade serous ovarian carcinoma
Benign serous ovarian tumour: a redefining moment?
Network vulnerability-based and knowledge-guided identification of microRNA biomarkers indicating platinum resistance in high-grade serous ovarian cancer